Robert Coleman is Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield. He graduated in medicine from Kings College Hospital Medical School and trained in London and Edinburgh before moving to Sheffield where he was instrumental in developing clinical cancer research in the city and establishing an internationally respected bone oncology research team. Professor Coleman held many leadership roles before his recent retirement from the University. He has written more than 450 scientific articles and 60 book chapters, is a past-president of the Cancer and Bone Society and was a trustee for Breast Cancer Now, the largest breast cancer research charity in the UK from 2010-2018. Currently he is a trustee at St Luke’s Hospice in Sheffield and the Weston Park Cancer Charity. Since 2014 he has been a part-time Medical Director for the global independent medical education provider, prIME Oncology™ developing and delivering both live and on-line educational programmes for oncologists and other providers of cancer care.
Christian Ottensmeier is Professor of Experimental Cancer Medicine at the University of Southampton. He graduated in Münster, Germany and began his specialist training there. After a 3-year training fellowship in the Dana Farber Cancer Institute in Boston, Massachusetts, he moved to Southampton where he leads the Experimental Cancer Medicine Centre. He has been a consultant in medical oncology since 2000. Clinically his interests are thoracic malignancies, head & neck cancer and melanoma, and he has co-developed a number of national NCRI studies in lung cancer. He is at the forefront of research into cancer vaccines and manages a broad and active clinical trials portfolio, including lung cancer and melanoma.
Poulam Patel is Professor of Clinical Oncology at the University of Nottingham and Honorary Consultant Medical Oncologist at the Nottingham University Hospitals NHS Trust. He combines laboratory research with clinical practice focussing on the development of new treatments for several cancer types including malignant melanoma and renal cancer. He has been principal investigator for many trials of novel therapies, including Scancell’s Phase 1/2 clinical trial of SCIB1-001 in melanoma patients. Professor Patel is currently the Chairman of the UK National Cancer Research Institute’s Skin Cancer Clinical Studies Group, the multidisciplinary committee charged with developing the national trials portfolio for skin cancer. He has previously been a National Cancer Specialty lead of the NIHR Clinical Research Network, the clinical trials arm of the NHS, and Chairman of the EORTC Melanoma Group, one of the world’s largest international melanoma clinical trials networks.
Iain McNeish is Professor of Oncology and Head of the Division of Cancer within the Department of Surgery and Cancer, Imperial College London. He is also the Director of the Ovarian Cancer Action Research Centre and Cancer theme lead in the Imperial NIHR Biomedical Research Centre (BRC). Externally, he is Chair of the NCRI Gynaecological Clinical Studies Group. His research focuses on ovarian cancer, specifically developing improved therapies through improved understanding of disease biology. He co-leads the BriTROC translational research collaborative and holds a programme grant from Cancer Research UK investigating copy number alterations in ovarian high-grade serous carcinoma as a possible prognostic and predictive biomarker.
David Miles is a consultant oncologist who specialises in breast cancer treatment, with over 20 years' experience in the field. Professor Miles was head of the Breast Cancer Biology Group at Guy's and St Thomas's, and more recently became Lead Clinician for breast cancer at Mount Vernon Cancer Centre. Professor Miles is the Global Principal Investigator in clinical trials of biological therapies in the treatment of breast cancer and serves on a number of clinical trial steering and independent data monitoring committees for studies of novel therapies for the treatment of breast and other cancers. Professor Miles also advises the National Institute for Health and Clinical Excellence (NICE) on the adoption of new drugs being considered for breast cancer.
Stephen Chan is the Director of Clinical Trials in Breast Cancer and Gynaecological Cancer at Nottingham University Hospital. For over two decades he has been at the forefront of researching and treating breast and gynaecological cancer, focussing on specialist treatment areas including chemotherapy, radiotherapy and targeted therapies. Professor Chan qualified at Nottingham University Medical School followed by further research and training at Oxford, Cambridge and London hospitals and universities. Professor Chan leads the Nottingham Personalised Therapy Oncology Research Group and the Breast & Gynaecological Clinical Trial Group with a particular interest in identifying new cancer genes and tests to select the best treatment for individual patients.
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Mon, 20 May 2019 09:51:00